Journal of Clinical Trials
Open Access

Shanghai HEP Pharmaceutical CO, Ltd, Shanghai, China

Publications

• Short Communication   
  Regulation of Bile Acids by an NTCP Inhibitor is Promising for the Treatment of Nonalcoholic Steatohepatitis
  Author(s): Cuili Fan, Hongli Liu* and Jian Wu*
  
  The beneficial effects of Hepalatide, an inhibitor of sodium taurocholate cotransporting polypeptide (NTCP), on the progression of nonalcoholic steato hepatitis was previously validated in mice. The underlying mechanismsare presumably associated with the profile changes of bile acids, which are natural agonistsfor FXR and TGR5receptors. In this short communication, the profile of bile acids and the metabolic changes in the liver or peripheral tissues were analyzed. It is our anticipation that using NTCP inhibitors, such as Hepalatide for the nonalcoholic steatohepatitis would be a clinically-applicable strategy.. View More»
  DOI: 10.35248/2167-0870.20.10.420

  Abstract HTML PDF